The utilization of tamoxifen is considerably high in Indonesia, with about 170,000 tamoxifen prescriptions filed in 2015. It is metabolized by the enzyme CYP2D6, resulting in its active metabolite, endoxifen, which has been proven to be effective in the prevention and treatment of breast cancer. Studies showed the CYP2D6 gene has more than 100 variants; some of which are linked with reduced drug activity, while others do not have any pathological implications. The metabolizer profile of these variants is generally grouped into Ultra-rapid, Normal, Intermediate, and Poor Metabolizers (UM, NM, IM, and PM, respectively). In our previous study (NCT04312347), the investigators recruited 150 breast cancer patients who were taking adjusted dose of tamoxifen daily based on their CYP2D6 phenotype. Although the investigators have measured the endoxifen level of the patients with adjusted treatment, the clinical outcomes of the study are not yet conclusive.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations
MRCCC Siloam Hospitals Semanggi
Jakarta, DKI Jakarta, Indonesia
Overall Survival rate
The percentage of study participants who are still alive by the end of this study after being diagnosed with breast cancer
Time frame: 3 year
Progression Survival rate
The percentage of study participants who live with the disease but the disease does not get worse by the end of this study
Time frame: 3 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.